PDL BioPharma interim CEO L. Patrick Gage resigns

Recs

0

PDL BioPharma Inc. said director and interim Chief Executive L. Patrick Gage resigned due to differences among the board about prioritizing company goals.

The biotechnology company previously announced that it is looking to separate its biotechnology assets into a separate publicly traded company; keep the rights to antibody humanization royalty revenue from current and future licensed products and distribute the income to stockholders; and continue to explore options to sell or securitize all or part of its antibody humanization royalties.

PDL said late Thursday that its three remaining board members will form a new Office of the Chair of the Board. The company also said board member Karen A. Dawes resigned for personal reasons.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 654976, ~/articles/articlehandler.aspx, 12/1/2008 9:21:52 AM,

Sign up for FREE Motley Fool site access to keep reading:

“PDL BioPharma interim CEO L. Patrick Gage resigns”

Signing up allows you to comment on articles and on the discussion boards.

It's completely FREE and will take only 10 seconds.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Most Recent

Most Recommended

Market Summary

S&P 500896.24+0.96%
DJIA8,829.04+1.17%
NASD1,535.57+0.23%
Updated: 1:04:05 PM
Sponsored by:

Related Tickers

PDL BioPharma, Inc.

CAPS Rating 4/5 Stars

$9.58

+0.21 (+2.24%)

Outperform500

Underperform33

Rate This Stock